Dr. Scott Kopetz, Prof. Eric Van Cutsem, and Dr. Josep Tabernero engage in a panel discussion with a focus on the practice-changing initial and subsequently updated mature findings from the BEACON trial. These pivotal findings alter the standard of care for patients with BRAF V600E-mutated metastatic colorectal cancer following first-line failure. Find out what you need to know about the latest studies so you can provide the best care for your patients with this condition.